ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of MR-guided Focused Ultrasound for Treatment of Refractory Major Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03421574
Recruitment Status : Recruiting
First Posted : February 5, 2018
Last Update Posted : August 6, 2018
Sponsor:
Information provided by (Responsible Party):
Dr. Nir Lipsman, Sunnybrook Health Sciences Centre

Brief Summary:
The proposed study is to evaluate the safety and initial efficacy of MRgFUS for patients with treatment-refractory Major Depression. This study is designed as a prospective, single arm, nonrandomized study. Assessments will be made before and after MRgFUS for adverse events related to treatment, for clinical symptom relief, and quality of life (QoL). The target in the brain chosen for ablation will be the anterior limb of the internal capsule (i.e 'capsulotomy').

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Device: MR-guided Focused Ultrasound Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Trial of MR-guided Focused Ultrasound (MRgFUS) Bilateral Capsulotomy for the Treatment of Refractory Major Depression
Actual Study Start Date : January 19, 2018
Estimated Primary Completion Date : December 7, 2018
Estimated Study Completion Date : December 7, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ultrasound

Arm Intervention/treatment
Experimental: MR-Guided Focused Ultrasound Device: MR-guided Focused Ultrasound
Focused Ultrasound allows for non-invasive thermal ablation of soft tissue virtually anywhere in the body. Treatment begins by acquiring a series of magnetic resonance (MR) images of the target tissue. The physician then reviews the images on the system workstation, identifies the target, delineates treatment contours, and reviews the treatment plan. Therapy planning software calculates the parameters required to effectively treat (e.g. ablate) the defined region. During treatment, the patient wears a helmet equipped with multiple sources of ultrasound which generate a point of focused energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, causing a thermal coagulation effect.




Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [ Time Frame: 1 year ]
    Safety of the ExAblate transcranial treatment will be determined by an evaluation of the incidence and severity of procedure related complications from the treatment day visit through the 12-month post-treatment time point. All events that are not procedure related will also be captured and recorded.


Secondary Outcome Measures :
  1. Quality of Life will be measured using the Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ) [ Time Frame: 1 year ]
    Q-LES-Q) is a self-report measure designed to enable investigators to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by subjects in various areas of daily functioning. The minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70.

  2. Clinical efficacy will be measured using the Hamilton Rating Scale for Depression (HAMD) [ Time Frame: 1 year ]

    The HAMD is designed to rate the severity of depression in patients. 0-7 = Normal 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression

    ≥ 23 = Very Severe Depression


  3. Clinical efficacy will be measured using the Montgomery Asberg Depression Rating Scale (MADRS) [ Time Frame: 1 year ]
    The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item clinician-administered scale, designed to be particularly sensitive to antidepressant treatment effects in patients with major depression. Higher scores indicate increasing depressive symptoms. Ratings can be added to form an overall score (range 0 to 50); no weights are used. Cut-off points include: 0 to 6 - symptom absent, 7 to 19 - mild depression, 30 to 34 - moderate, 35 to 60 - severe depression.

  4. Clinical efficacy will be measured using the Beck Depression Inventory (BDI) [ Time Frame: 1 year ]
    BDI is a self-rated depression scale. 1-10:These ups and downs are considered normal;11-16: Mild mood disturbance; 17-20: Borderline clinical depression; 21-30: Moderate depression; 31-40: Severe depression; over 40: Extreme depression.

  5. Clinical efficacy will be measured using the Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: 1 year ]
    C-SSRS is a suicidal ideation rating scale created by researchers at Columbia University to evaluate suicidality in children ages 12 and up.[1] It rates an individual's degree of suicidal ideation on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent."



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men and women ≥20 and ≤80 years of age.
  2. Patients who are able and willing to give consent and physically and practically able to attend study visits, as determined by both study Psychiatrist and the surgeon.
  3. DSM-V diagnosis of major depressive episode, as a component of an Axis I disorder, such as Major Depressive Disorder, Bipolar Disorder, Anxiety Disorder, Eating Disorder, Substance Abuse/Dependence Disorder ,or Personality Disorder
  4. At least 5-year illness history of the primary disorder and at least 6 months since the onset of the first episode of major depression.
  5. A minimum score of 20 on the Hamilton Depression Rating Scale (HAMD) when depressed (patients with bipolar disorder may be rapid cycling, but have to have at least 2 weeks of major depression at the time the HAMD is conducted)
  6. Medication-refractoriness as determined by an adequate dose and duration of standard psychiatric treatments (including psychotherapy and/or pharmacology) as determined by two psychiatrists associated with the study. Including specifically:

    1. Failed to respond or tolerate adequate trial of three or more medications accepted as first line in the treatment of depression
    2. Failed to respond or tolerate augmentation with or combination,of at least 2 medications known to be first line treatments for depression
    3. An adequate trial of cognitive behavioural therapy or other evidence-supported psychotherapy, delivered by a therapist experienced in treating depression
  7. Able to communicate sensations during the ExAblate MRgFUS treatment
  8. A consistent dose of any and all medications in the 30 days prior to study entry.
  9. Women of childbearing potential must agree to use a contraception method throughout the study.

Exclusion Criteria:

  1. Patients with unstable cardiac status [e.g. Unstable angina pectoris on medication, Patients with documented myocardial infarction within six months, Congestive heart failure requiring medication (other than diuretic), Patients on anti-arrhythmic drugs, Severe hypertension (diastolic BP > 100 on medication)]
  2. Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.
  3. Severely impaired renal function (estimated glomerular filtration rate < 30ml/min/1.73 m2) or receiving dialysis
  4. Laboratory biochemical evidence of abnormal bleeding and/or coagulopathy, including risk factors for intraoperative or postoperative bleeding (platelet count less than 100,000 per cubic millimeter or abnormal INR)
  5. Cerebrovascular disease (e.g. CVA within 6 months) or history of intracranial hemorrhage
  6. Untreated, uncontrolled sleep apnea
  7. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure
  8. Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment
  9. Are participating or have participated in another clinical trial in the last 30 days
  10. Patients unable to communicate with the investigator and staff.
  11. Presence of significant cognitive impairment
  12. Presence of psychosis on clinical evaluation.
  13. Patients with brain tumors already known or revealed on pretreatment MRI
  14. Currently pregnant (as determined by history and serum HCG) or lactating.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03421574


Contacts
Contact: Anusha Baskaran, PhD 416-480-6100 ext 1650 anusha.baskaran@sunnybrook.ca

Locations
Canada, Ontario
Sunnybrook Health Sciences Centre Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Anusha Baskaran, PhD    416-480-6100 ext 1650    anusha.baskaran@sunnybrook.ca   
Sponsors and Collaborators
Sunnybrook Health Sciences Centre

Responsible Party: Dr. Nir Lipsman, Princiapl Investigator, Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier: NCT03421574     History of Changes
Other Study ID Numbers: 344-2017
First Posted: February 5, 2018    Key Record Dates
Last Update Posted: August 6, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Depression
Depressive Disorder
Depressive Disorder, Major
Behavioral Symptoms
Mood Disorders
Mental Disorders